KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $2.2 billion.

  • Teva Pharmaceutical Industries' Cost of Revenue fell 0.32% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 billion, marking a year-over-year decrease of 0.46%. This contributed to the annual value of $8.5 billion for FY2024, which is 3.43% up from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Cost of Revenue stood at $2.2 billion, which was up 4.92% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Cost of Revenue registered a high of $2.2 billion during Q3 2024, and its lowest value of $1.9 billion during Q1 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $2.1 billion (2023), whereas its average is $2.1 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Cost of Revenue fell by 14.76% in 2021, and later rose by 9.20% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cost of Revenue (Quarterly) stood at $2.0 billion in 2021, then increased by 3.07% to $2.1 billion in 2022, then fell by 3.41% to $2.0 billion in 2023, then increased by 3.33% to $2.1 billion in 2024, then decreased by 0.32% to $2.2 billion in 2025.
  • Its Cost of Revenue was $2.2 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $2.0 billion in Q1 2025.